- Home
- GHY vs ALMS Comparison
GHY vs ALMS Comparison
Compare GHY & ALMS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GHY
- ALMS
- Stock Information
- Founded
- GHY 2012
- ALMS 2021
- Country
- GHY United States
- ALMS United States
- Employees
- GHY N/A
- ALMS N/A
- Industry
- GHY Trusts Except Educational Religious and Charitable
- ALMS
- Sector
- GHY Finance
- ALMS
- Exchange
- GHY Nasdaq
- ALMS NYSE
- Market Cap
- GHY 484.9M
- ALMS 402.6M
- IPO Year
- GHY N/A
- ALMS 2024
- Fundamental
- Price
- GHY $13.25
- ALMS $2.86
- Analyst Decision
- GHY
- ALMS Strong Buy
- Analyst Count
- GHY 0
- ALMS 7
- Target Price
- GHY N/A
- ALMS $24.50
- AVG Volume (30 Days)
- GHY 184.8K
- ALMS 1.1M
- Earning Date
- GHY 01-01-0001
- ALMS 08-12-2025
- Dividend Yield
- GHY 10.58%
- ALMS N/A
- EPS Growth
- GHY N/A
- ALMS N/A
- EPS
- GHY N/A
- ALMS N/A
- Revenue
- GHY N/A
- ALMS $17,389,000.00
- Revenue This Year
- GHY N/A
- ALMS N/A
- Revenue Next Year
- GHY N/A
- ALMS N/A
- P/E Ratio
- GHY N/A
- ALMS N/A
- Revenue Growth
- GHY N/A
- ALMS N/A
- 52 Week Low
- GHY $10.24
- ALMS $2.81
- 52 Week High
- GHY $11.92
- ALMS $13.53
- Technical
- Relative Strength Index (RSI)
- GHY 57.89
- ALMS N/A
- Support Level
- GHY $13.20
- ALMS N/A
- Resistance Level
- GHY $13.43
- ALMS N/A
- Average True Range (ATR)
- GHY 0.09
- ALMS 0.00
- MACD
- GHY -0.01
- ALMS 0.00
- Stochastic Oscillator
- GHY 45.45
- ALMS 0.00
About GHY PGIM Global High Yield Fund Inc.
PGIM Global High Yield Fund, Inc is a diversified, closed-end management investment company. The fund's investment objective is to provide a high level of current income. The fund seeks to provide a high level of current income by investing in higher-rated, below-investment-grade fixed income instruments of issuers located around the world, including emerging markets.
About ALMS ALUMIS INC
Alumis Inc is a clinical-stage biopharmaceutical company focused on identifying, acquiring, and accelerating the development and commercialization of transformative medicines for autoimmune disorders. The Company leverages its proprietary precision data analytics platform, biological insights, and a team of experts with deep experience in precision medicine drug discovery, development, and immunology, to create medicines that significantly improve the lives of patients by replacing broad immunosuppression with targeted therapies. Company pipeline includes: ESK-001, TYK2, A-OO5, IRF5.